Neuroservices-Alliance’s Post

DRG are the first “integration center” on the pain pathways. This is the first level where pharmacological modulation can take place. We offer all the ways (in vitro and in vivo) to investigate the pharmacological properties of your compound on sensory neurons!

⏰ It's not too late to register! You won't want to miss our webinar, "iForum™ Innovation Showcase 2024: Implementing Human iPSC Models to Speed Drug Discovery and Improve Clinical Translation" on January 30, 2024 (9:00 AM- 11:00 AM EST). Join us as FCDI's leading scientists dive into the transformative power of advanced biological models. We're talking about breakthroughs that are reshaping our approach to accelerating drug discovery across cardiac, hepatic, neural, and immune systems. Come for specific talks or immerse yourself in the entire 2-hour presentation – the choice is yours! 👉 VIEW DETAILED AGENDA AND REGISTER NOW! https://ow.ly/vupM50Qs8sP #StemCells #iPSC #DrugDiscovery #DrugDevelopment #Neuroscience #DiseaseModeling #3DCellCuture #Neuroinflammation #SafetyPharmacology #CardiacSafety #CardioTox

At EphyX Neuroscience, we're committed to what truly matters to our clients: exceptional data quality, adaptive protocols, and swift delivery. Partner with us for your electrophysiology data needs and expect: ✅ Unmatched Protocol Flexibility: - On-the-go adjustments, even on short notice. - Pause or stop ongoing contracts if data doesn't support further collection. ✅ Diverse Technical Approaches: Including patch clamp, optogenetics, calcium imaging, organotypic slice cultures and iPSC-derived human neuronal cultures. ✅ Expert Team: Dedicated PhD experimenters with extensive experience in their fields. ✅ High-Quality, Actionable Data: Empowering you to make informed, optimized decisions. 🌐 Discover more about our services: www.ephyx-neuroscience.com ✉️ Have questions? Let's connect: contact@ephyx-neuroscience.com We're eager to support your electrophysiology data needs and help drive your success! #Electrophysiology #DrugDiscovery #CNSResearch #DrugDevelopment #PreclinicalResearch #ResearchAndDevelopment #Neurophysiology #CentralNervousSystem #Neuroscience #CRO #Pharma #ContractResearch

Our #Alto #digitalSPR platform played a crucial role in the development of DART.2 (Drug Acutely Restricted by Tethering), an innovative method for highly targeted #drugdelivery to specific types of neurons in the brain. Led by Dr. Mike Tadross at Duke University DART.2 has the potential to revolutionize how we study and treat #neurological diseases. By using Alto, researchers were able to precisely measure the binding kinetics of key molecules, ensuring the effectiveness of DART.2. We’re proud to support cutting-edge research with our next-gen #SPR platforms, enabling scientists to push the boundaries of what's possible in #drugdiscovery and #neuroscience. Read the full blog post here: https://lnkd.in/gpYitjSA

A novel engineered assembloid platform may help accelerate therapeutic discovery for Parkinson’s disease (PD). Congratulations to Alp Ozgun, David Lomboni, Fabio Variola, and their team, for the important paper 📝 describing the development of a novel engineered assembloid platform to recapitulate key attributes of PD dysfunction in vitro. Visit our website to learn more and discover how the researchers used Axion’s next-generation Maestro Pro MEA platform to explore the dysfunctional dopaminergic network associated with PD in real time with no labels, dyes, or complicated steps.  🔗 https://bit.ly/3PGneLr #parkinsonsdiseaseresearch #iPSCs #neuroscience

🚀 Neuroproof and Doppelganger Join Forces for ALS Research! 🧬   Exciting news in ALS research! Neuroproof and Doppelganger have launched a cutting-edge ALS screening service that combines metabolic and electrophysiological analysis. This innovative service dives deep into energy metabolism, revealing how disrupted pathways in ALS cells, like mitochondrial dysfunction and oxidative stress, fuel disease progression. With Neuroproof's advanced biomarker assays and Doppelganger's QSM™ platform, they’re analyzing 22 key metabolic pathways, including glycolysis and OXPHOS. This powerful combination helps improve drug screening accuracy and uncovers new therapeutic targets. A step closer to unlocking breakthroughs in ALS treatment! 💡   #ALSResearch #Neuroproof #Doppelganger #MetabolicAnalysis #Biomarkers #DrugDiscovery #Neuroscience

Robust electrophysiological characterization of Human iPSC-derived neurons by NEUROSERVICES-ALLIANCE => see our poster at SfN meeting in Chicago!!!

⏰WEBINAR - Last Chance to Register! Join us on October 23, 2024 (11:00 AM EST) for our webinar, "Scientific Shorts: Neuroscience 2024 Poster Recap with New iPSC-derived Cell Types and Applications". ✔️LEARN MORE AND REGISTER NOW! https://ow.ly/LkcU50TL7km During this webinar, we will review the exciting scientific research FCDI presented at Neuroscience 2024 as four 10-minute talks. Key topics include: ✔️Optimization of cytokine release assays for iCell® Microglia and the role of healthy microglia and TREM2 variants in neuroprotection and neurodegeneration. (Michelle Curtis) ✔️Assays to evaluate iCell Sensory Neurons function and techniques to investigate immune-mediated neuropathic pain and CIPN. (Scott Schachtele) ✔️Assessment of the BBB for drug permeability and disease studies in a high-throughput fashion using the iCell Blood-Brain Barrier Kit. (Ravi Vaidyanathan) ✔️Using Agilent Seahorse XF to detect differences in mitochondrial function between various healthy and diseased iCell neural products. (Coby Carlson) Can't attend live? Not a problem! All registrants will receive access to the recording post-webinar. We hope to see you there! #neuroscience #drugdiscovery #iPSC #diseasemodeling #bloodbrainbarrier #neurodegeneration #painresearch #neuropathy

Are you developing drugs targeting #CNS diseases?  At Neuroservices-Alliance, our team of expert neuroscientists benefits from over 17 years of experience in developing brain slice electrophysiology assays. Explore our cutting-edge solutions: 🔹 Investigate neuronal activity 🔹 Study synaptic responses 🔹 Test drug effects Consult our attached one-pager for details and reach out at contact@neuroservices-alliance.com to discuss your ongoing research. #neuroscience #research #electrophysiology #MOA #neuronalactivity #drugdiscovery

𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗶𝗻𝗴 𝗲𝘅𝗰𝗶𝘁𝗮𝘁𝗼𝗿𝘆 𝗻𝗲𝘂𝗿𝗼𝗻𝘀 𝘄𝗵𝗶𝗹𝗲 𝗸𝗲𝗲𝗽𝗶𝗻𝗴 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘆 𝗻𝗲𝘂𝗿𝗼𝗻𝘀 𝗮𝗰𝘁𝗶𝘃𝗲 𝗶𝘀 𝗰𝗿𝘂𝗰𝗶𝗮𝗹 𝗳𝗼𝗿 𝘁𝗿𝗲𝗮𝘁𝗶𝗻𝗴 𝘀𝗲𝗶𝘇𝘂𝗿𝗲 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀 In a recent study, Goodchild et al. provided a comprehensive analysis of a new class of small molecules that, at nanomolar concentrations, selectively target the inhibition of NaV1.6 and NaV1.2 channels, primarily found on excitatory neurons, with minimal impact on NaV1.1 channels, prevalent in GABAergic neurons. They discovered that XPC-5462 inhibits both NaV1.6 and NaV1.2 channels, whereas XPC-7224 exclusively targets NaV1.6. 𝗪𝗵𝗮𝘁 𝗮𝗿𝗲 𝘁𝗵𝗲 𝗳𝘂𝗻𝗰𝘁𝗶𝗼𝗻𝗮𝗹 𝗰𝗼𝗻𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗲𝘀 𝗼𝗳 𝘁𝗵𝗶𝘀? To elucidate this, Goodchild and colleagues reproduced #epilepsy-like events in #brainslices while monitoring electrical activity with 𝗔𝗰𝗰𝘂𝗿𝗮 𝗛𝗗-𝗠𝗘𝗔 𝗰𝗵𝗶𝗽𝘀. Their findings reveal that XPC-5462 reduces the occurrence of seizure-like activity and epileptiform discharges, while XPC-7224 does not lead to significant reductions. This study introduces new drugs with enhanced affinity and specificity for safer treatment of seizure disorders and emphasizes the crucial role of NaV1.2 channels in both ex vivo and potentially in vivo contexts. Congratulations to Samuel Goodchild and the team for these findings. Read the paper here: https://lnkd.in/eAbsVahA #epilepsy #electrophysiology #neuroscience #neurosciencebreakthrough #researchrevolution #understandingthebrain #futureofneuroscience #neurosciencecommunity #scientificadvancements #neuroscienceexploration #researchadvancement